Inreda Diabetic B.V. is investigating the efficacy of Lyumjev, an ultrarapid insulin, in a bihormonal closed-loop system designed for automated glucose regulation in Type 1 Diabetes patients. This multicenter, open-label, randomized, cross-over trial aims to demonstrate that Lyumjev can outperform standard Humalog therapy in terms of glycemic control, specifically by reducing the time spent above target glucose levels. The successful demonstration of Lyumjev's efficacy could position Inreda favorably in the competitive landscape of diabetes management technologies, particularly as the demand for advanced insulin delivery systems continues to grow. The results may also enhance the commercial viability of Lyumjev in combination with Inreda's artificial pancreas technology, potentially leading to expanded market opportunities and partnerships. Given the increasing prevalence of diabetes, the asset could attract significant interest from investors and collaborators focused on innovative diabetes solutions.